📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-01 17:55
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
Sat Kartar Life Plans ₹9.46 Cr Preferential Warrant Issue to Promoters; Calls EGM on Oct 23
Sat Kartar Life Limited has issued a notice convening an Extraordinary General Meeting (EGM) on October 23, 2026, to seek shareholder approval for issuing up to 5,50,000 fully convertible warrants on a preferential basis to the promoter/promoter group. The warrants are priced at ₹172 each, totaling up to ₹9.46 crore. A minimum of 25% (₹2.365 crore) is payable on subscription, with the remaining 75% (₹7.095 crore) due upon warrant conversion within 18 months. The cut-off date for e-voting is October 16, 2026.
Confidence: HIGH
What changedThe company has formally notified shareholders of an EGM to approve a ₹9.46 crore preferential warrant allotment to promoters.
Why it mattersThe infusion of ₹9.46 crore provides growth capital to support ongoing expansions while signaling promoter financial commitment.
Warrants issue size: ₹9,46,00,000Number of warrants: 5,50,000Issue price per warrant: ₹172Upfront subscription (25%): ₹2,36,50,000EGM Date: October 23, 2026
📅 Short termMarket sentiment may be supported by promoter capital backing, with focus shifting to the shareholder vote on October 23, 2026.
📈 Long termIf converted over the 18-month window, the ₹9.46 crore equity capital will strengthen the balance sheet and modestly expand the equity base.
⚠ Risk flags
- Equity dilution upon full conversion of 5,50,000 warrants
- Promoter warrants carry an 18-month exercise window; conversion is contingent on full payment of the remaining 75%
Key Highlights
Proposed issuance of up to 5,50,000 fully convertible warrants at ₹172 each to the promoter/promoter group
Total capital planned to be raised is up to ₹9.46 crore (₹9,46,00,000)
25% upfront subscription payable equals ₹2.365 crore (₹2,36,50,000), with 75% (₹7.095 crore) upon conversion within 18 months
E-voting period runs from October 20, 2026 to October 22, 2026, ahead of the EGM on October 23, 2026
👀 What to Watch
Track the voting outcome of the EGM on October 23, 2026, and monitor subsequent warrant subscription and allotment within the regulatory 15-day timeline.
Sat Kartar Life Board Approves ₹9.46 Cr Convertible Warrants to Promoters at ₹172/Share
Sat Kartar Life Limited's Board has approved the issuance of up to 5,50,000 convertible warrants on a preferential basis to promoter group entities, raising up to ₹9.46 crore. The issue price is fixed at ₹172 per warrant, which is an 18.20% premium over the SEBI ICDR floor price of ₹145.51. Upon full conversion within 18 months, promoter shareholding will increase from 54.20% to 55.52%. The company has scheduled an Extraordinary General Meeting (EGM) on October 23, 2026, to seek shareholder approval, with a voting cut-off date of October 16, 2026.
Confidence: HIGH
What changedThe Board approved a ₹9.46 crore preferential warrant issue entirely to promoters at an 18.20% premium over the floor price.
Why it mattersPromoters are injecting fresh equity at a premium, signaling confidence and strengthening capital for business expansion in Ayurveda and hospital services without external leverage.
Total Fundraise Amount: ₹9,46,00,000Number of Warrants: 5,50,000Issue Price per Warrant: ₹172Floor Price: ₹145.51Premium over Floor Price: 18.20%Post-Issue Promoter Holding: 55.52%
📅 Short termPositive sentiment likely due to promoters infusing capital at an 18.2% premium over the statutory floor price. Focus shifts to the EGM on October 23, 2026.
📈 Long termProvides incremental growth capital to scale its integrated healthcare and hospital services platform while modestly increasing promoter alignment.
⚠ Risk flags
- Dilution of public shareholding from 45.80% to 44.48%
- Warrant holders have up to 18 months to convert; remaining 75% capital inflow is contingent on conversion
Key Highlights
Preferential issuance of up to 5,50,000 convertible warrants at ₹172 each, totaling ₹9.46 crore
Issue price is at an 18.20% premium above the SEBI ICDR floor price of ₹145.51
Promoter holding to increase from 54.20% to 55.52% post full conversion
25% upfront subscription payable immediately, with the remaining 75% due within an 18-month tenure
Shareholder approval to be sought at an EGM on October 23, 2026 (cut-off date: October 16, 2026)
👀 What to Watch
Track voting results from the October 23, 2026 EGM and subsequent receipt of the 25% upfront subscription capital. Monitor deployment of funds into the Ayurveda products and hospital platform expansions.
Sat Kartar Life Board Approves ₹9.46 Cr Preferential Issue of Convertible Warrants to Promoters
Sat Kartar Life Limited's board has approved the issuance of up to 5,50,000 convertible warrants at ₹172 each, raising up to ₹9.46 crore on a preferential basis. The warrants are being allocated exclusively to members of the promoter and promoter group at an 18.20% premium over the SEBI floor price of ₹145.51. Upon full conversion within the 18-month tenure, promoter shareholding will rise from 54.20% to 55.52%. The company has convened an Extra Ordinary General Meeting on October 23, 2026, to seek shareholder approval.
Confidence: HIGH
What changedThe Board approved a preferential issuance of 5.50 lakh warrants at ₹172 to promoters, raising up to ₹9.46 crore.
Why it mattersPromoters are injecting fresh capital at an 18.20% premium to the statutory floor price, bolstering capital for Ayurvedic product and hospital healthcare operations while increasing their equity stake.
Total Fundraise Amount: ₹9,46,00,000Number of Warrants: 5,50,000Warrant Issue Price: ₹172Floor Price: ₹145.51Promoter Post-Issue Holding: 55.52%
📅 Short termPositive sentiment likely due to promoters infusing capital at a sizeable premium above the SEBI minimum floor price. Focus shifts to the October 23 EGM.
📈 Long termProvides incremental growth capital to expand hospital services and Ayurvedic platforms, though equity dilution of ~2.97% will apply across 18 months.
⚠ Risk flags
- Dilution risk of ~2.97% to existing public equity base upon conversion
- Requires approval from shareholders at the upcoming EGM
- Warrant conversion spans up to 18 months, delaying final cash realization
Key Highlights
Approved issuance of 5,50,000 convertible warrants aggregating up to ₹9,46,00,000
Issue price set at ₹172 per warrant, representing an 18.20% premium over the SEBI floor price of ₹145.51
Promoter holding to increase from 54.20% (1,00,21,556 shares) to 55.52% (1,05,71,556 shares) post full conversion
25% payable upfront upon subscription, with remaining 75% payable within an 18-month warrant tenure
Shareholder approval scheduled via EGM on October 23, 2026, with cut-off date set as October 16, 2026
👀 What to Watch
Track shareholder voting outcomes at the EGM on October 23, 2026, and monitor subsequent warrant subscription inflows and conversion timelines.
Sat Kartar Signs LOI to Add 20-Bed Ayurvedic Hospital in Dehradun for ₹70 Lakh
Sat Kartar Life Limited has signed a Letter of Intent (LOI) to establish a new 20-bed hospital-cum-therapy centre on Rajpur Road, Dehradun, Uttarakhand. The facility will span approximately 7,000 sq. ft. with an estimated investment of ₹70 Lakh funded via IPO funds. It is targeted to be operational by December 15, 2026, subject to regulatory approvals. This move aligns with the company's stated strategy to vertically integrate into high-margin (25-30% EBITDA) Ayurvedic hospital services.
Confidence: HIGH
What changedThe company entered into an LOI to set up a new 20-bed hospital and therapy centre in Dehradun.
Why it mattersThe ₹70 Lakh capex allows the company to vertically expand into Ayurvedic hospital operations, a segment management projects to generate 25-30% EBITDA margins.
Bed Capacity: 20 BedsEstimated Investment: ₹70 LacsFacility Area: 7000 sq. ft.Operational Target Date: 15th December, 2026
📅 Short termNeutral to mildly positive as the announcement is currently at the Letter of Intent stage with a modest initial capex outlay.
📈 Long termIf successfully scaled and replicated, the transition into hospital-cum-therapy centres supports diversification from pure D2C wellness products into higher-margin integrated wellness services.
⚠ Risk flags
- Preliminary LOI stage; subject to definitive agreements and statutory healthcare licences
- Execution and operational delays ahead of the December 2026 launch target
Key Highlights
Signs Letter of Intent for a 20-bed Hospital-cum-Therapy Centre in Dehradun, Uttarakhand
Facility spread across approximately 7,000 sq. ft. with an estimated investment of ₹70 Lakh
Funded through IPO funds, targeted to be operational by December 15, 2026
Supports strategic expansion into Ayurveda-based therapies and integrated wellness
👀 What to Watch
Track the signing of definitive agreements and the receipt of regulatory licences ahead of the targeted December 15, 2026 commissioning date.
₹1 Cr Investment for New 10-15 Bed Ayurvedic Hospital in Gurugram
Sat Kartar Life Limited is establishing a new 4,000 sq. ft. hospital-cum-therapy centre in Gurugram, Haryana, with an estimated investment of ₹1 crore. The facility will feature 10-15 beds and is slated to become operational by October 15, 2026, funded through IPO proceeds. This expansion aligns with the company's strategy to enter the high-margin Ayurvedic hospital segment, which targets 25-30% EBITDA margins. While the capex is small (~0.9%) relative to the March 2026 quarterly revenue of ₹110.62 crore, it represents a key vertical integration step.
Confidence: HIGH
What changedThe company is expanding its business model from purely D2C Ayurvedic products to include physical healthcare infrastructure and therapy services.
Why it mattersThis vertical expansion into hospital services is expected to be EBITDA accretive and provides a higher-margin revenue stream compared to traditional product sales.
Estimated Investment: ₹1 croreProposed Bed Capacity: 10-15 bedsEstimated Area: 4,000 sq. ft.Operational Date: 15th October, 2026Investment vs Mar 2026 Revenue: ~0.9%
📅 Short termThe announcement is likely to be viewed positively as it demonstrates the deployment of IPO funds into high-margin expansion projects.
📈 Long termIf successful, the transition to a service-integrated model could improve customer retention and structural margins over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory approvals for hospital operations
- Execution risk in managing physical healthcare facilities
- Small scale of initial investment relative to total revenue
Key Highlights
Investment of approximately ₹1 crore to be funded via IPO proceeds
Proposed capacity addition of 10-15 beds in a 4,000 sq. ft. facility
Expected commencement of operations by 15th October, 2026
Targeting high-margin Ayurvedic hospital services with 25-30% EBITDA margins
Strategic location in Sector 68, Gurugram to strengthen healthcare network
👀 What to Watch
Monitor the timely commencement of operations by October 2026 and subsequent updates on capacity utilization, which the company targets at 80-90% within the first year.
₹1 Cr Investment: Sat Kartar to Open New 10-15 Bed Ayurvedic Hospital in Gurugram
Sat Kartar Life Limited has announced the establishment of a new hospital-cum-therapy centre in Gurugram, Haryana, with an estimated investment of ₹1 crore. The facility, spanning 4,000 sq. ft., will have a capacity of 10-15 beds and is expected to be operational by October 15, 2026. This move aligns with the company's strategy to diversify into high-margin (25-30% EBITDA) Ayurvedic hospital services, funded entirely through IPO proceeds. This represents a vertical expansion from their existing D2C wellness product business into physical healthcare infrastructure.
Confidence: HIGH
What changedThe company is transitioning from a purely D2C product-based model to include physical healthcare service infrastructure.
Why it mattersThis vertical integration allows the company to monetize its existing customer base through high-ticket hospital services, which carry significantly higher EBITDA margins (25-30%) compared to standard retail products.
Estimated Investment: ₹1 croreProposed Bed Capacity: 10-15 bedsFacility Area: 4,000 sq. ft.Target Operational Date: 15th October, 2026Investment vs Mar 2026 Quarterly Revenue: ~0.90%
📅 Short termThe announcement is likely to be viewed positively as a concrete step toward high-margin diversification, though the immediate financial impact is small relative to quarterly revenue.
📈 Long termIf successful, this pilot hospital could serve as a blueprint for a scalable, high-margin service model that complements their existing Ayurvedic product portfolio.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in managing physical hospital operations
- Regulatory approval delays for healthcare licenses
- Dependence on achieving high utilization (80-90%) for profitability
Key Highlights
Estimated investment of approximately ₹1 crore to be funded via IPO proceeds
Proposed bed capacity of 10-15 beds in a 4,000 sq. ft. covered facility
Target operational date set for October 15, 2026, pending regulatory approvals
Strategic expansion into Ayurvedic hospital services targeting 25-30% EBITDA margins
Location finalized at Tower B, 68 Avenue, Sector 68, Gurugram
👀 What to Watch
Monitor the commencement of operations by the October 15 deadline and track subsequent capacity utilization, as the company targets 80-90% utilization within 12 months of opening.
₹0.70 Dividend and ₹164.5 Cr Related Party Transactions Proposed in 14th AGM Notice
Sat Kartar Life Limited has scheduled its 14th AGM for August 28, 2026, to approve a final dividend of ₹0.70 per share for FY 2025-26. The company is seeking shareholder approval for significant Related Party Transactions (RPT) totaling ₹164.5 crore for FY 2026-27, primarily for trade and marketing with subsidiaries. For the full year FY 2025-26, the company reported a net profit of ₹17.10 crore, a significant increase from ₹9.81 crore in the previous year. The record date for dividend eligibility is set for August 21, 2026.
Confidence: HIGH
What changedThe company has formalized its AGM schedule, dividend payout details, and sought authorization for substantial inter-company transactions for the next year.
Why it mattersThe proposed RPT limit of ₹164.5 crore is significant compared to the company's quarterly revenue of ₹110.62 crore, indicating a business model heavily reliant on subsidiary-led distribution and marketing.
Dividend per share: ₹0.70Total RPT Limit (FY27): ₹164.5 crFY26 Net Profit: ₹17.10 crRPT vs Annualized Revenue: ~37%Record Date: August 21, 2026
📅 Short termThe stock may see neutral to slightly positive interest leading up to the dividend record date of August 21.
📈 Long termThe company's long-term trajectory depends on the successful integration of its subsidiaries and the efficiency of its high-spend D2C marketing model.
⚠ Risk flags
- High volume of Related Party Transactions (₹164.5 cr)
- Heavy reliance on subsidiary-led trade
- High customer acquisition costs in the D2C segment
Key Highlights
Proposed final dividend of ₹0.70 per equity share (7% of face value) for FY 2025-26
Total Related Party Transactions (RPT) limit of ₹164.5 crore proposed for the 2026-27 fiscal year
Individual RPT limits of ₹40 crore each established for subsidiaries Plantomed, Ajooni, Sat Kartar Ocean, and Sat Kartar USA
Annual net profit for FY 2025-26 reported at ₹17.10 crore based on surplus accounts
Re-appointment of M/s. Nidhi Bansal & Co. as Statutory Auditors for a five-year term until 2031
👀 What to Watch
Investors should monitor the approval of the high-value Related Party Transactions at the AGM and track the execution of the US expansion through the newly formed subsidiary Sat Kartar USA INC.
₹0.70 Final Dividend Recommended; Record Date Set for August 21, 2026
Sat Kartar Life Limited has recommended a final dividend of ₹0.70 per equity share (7% of face value) for the financial year ended March 31, 2026. The Board has fixed August 21, 2026, as the record date for determining shareholder eligibility for the dividend and AGM e-voting. The 14th Annual General Meeting is scheduled for August 28, 2026. This follows a March 2026 quarter where the company reported a net profit of ₹9.80 crore on revenue of ₹110.62 crore.
Confidence: HIGH
What changedThe company has transitioned from its financial reporting phase to the dividend distribution and annual governance phase for FY26.
Why it mattersThe dividend payout confirms the company's intent to return capital to shareholders following a profitable quarter. The re-appointment of auditors for five years provides stability in financial oversight.
Final Dividend: ₹0.70 per shareDividend as % of Face Value: 7%Record Date: 21-Aug-2026AGM Date: 28-Aug-2026Mar 2026 Net Profit: ₹9.80 cr
📅 Short termThe stock may experience neutral to slightly positive sentiment as it approaches the record date for the dividend payout.
📈 Long termThe dividend is routine; long-term value will be driven by the company's ability to scale manufacturing utilization from 10% to 50% and execute its US D2C expansion.
⚠ Risk flags
- High customer acquisition costs (2.6% conversion for paid search)
- Supply chain risks linked to geopolitical instability
Key Highlights
Recommended a final dividend of ₹0.70 per equity share of face value ₹10 each
Fixed August 21, 2026, as the record date for dividend payment and AGM e-voting
Scheduled the 14th Annual General Meeting for August 28, 2026, via video conferencing
Proposed re-appointment of M/S. Nidhi Bansal & Co. as statutory auditors for a 5-year term
Reported March 2026 quarterly EPS of ₹6.22
👀 What to Watch
Investors seeking the dividend should ensure they hold the shares before the ex-dividend date (typically one business day prior to the August 21 record date). Monitor the AGM for updates on the proposed US market expansion and Ayurvedic hospital margins.
₹0.70 Dividend Recommended; 14th AGM Scheduled for August 28, 2026
Sat Kartar Life Limited has recommended a final dividend of ₹0.70 per equity share (7% of ₹10 face value) for the financial year ended March 31, 2026. The 14th Annual General Meeting (AGM) is scheduled for August 28, 2026, with the record date for dividend eligibility set as August 21, 2026. The board also approved the re-appointment of M/S. Nidhi Bansal & Co. as statutory auditors for a five-year term. This follows a March 2026 quarter where the company reported a net profit of ₹9.80 crore on revenue of ₹110.62 crore.
Confidence: HIGH
What changedThe company has formalized its FY26 dividend payout and scheduled its annual shareholder meeting and auditor re-appointment.
Why it mattersThe dividend provides a tangible yield to shareholders, while the 5-year auditor term ensures continuity in financial governance during the company's planned expansion phase.
Dividend per share: ₹0.70Record Date: August 21, 2026AGM Date: August 28, 2026Mar 2026 Revenue: ₹110.62 crMar 2026 Net Profit: ₹9.80 crAuditor Term: 5 years
📅 Short termThe stock may see mild positive interest leading up to the August 21 record date as investors position for the dividend payout.
📈 Long termLimited structural impact from this routine filing; long-term value depends on the execution of the AI-driven sales model and Ayurvedic hospital expansion.
Key Highlights
Final dividend of ₹0.70 per equity share of face value ₹10 recommended for FY26.
Record date for dividend distribution and E-voting eligibility fixed for August 21, 2026.
14th Annual General Meeting scheduled for August 28, 2026, via video conferencing.
Proposed re-appointment of Statutory Auditors for a 5-year term starting from the ensuing AGM.
March 2026 quarterly revenue was ₹110.62 crore with an EPS of ₹6.22.
👀 What to Watch
Investors should note the record date of August 21, 2026, for dividend eligibility and watch for management commentary during the August 28 AGM regarding US market expansion plans.
Sat Kartar Life Recommends ₹0.70 Dividend and Re-appoints Auditor for 5 Years
Sat Kartar Life Limited has recommended a final dividend of ₹0.70 per equity share (7% of face value) for FY26, following a March 2026 quarter where it reported a net profit of ₹9.80 crore. The board also approved the re-appointment of M/S. Nidhi Bansal & Co. as statutory auditors for a five-year term, ensuring continuity in financial oversight. The record date for the dividend and the 14th Annual General Meeting (AGM) e-voting has been set for August 21, 2026. The AGM is scheduled for August 28, 2026, to seek shareholder approval for these proposals.
Confidence: HIGH
What changedThe company has transitioned from its board-level proposal to formalizing the dividend payout and auditor tenure extension for shareholder approval.
Why it mattersThe dividend provides a tangible cash return to shareholders, representing approximately 11.25% of the reported March quarter EPS of ₹6.22, while the auditor re-appointment maintains governance stability.
Final Dividend: ₹0.70 per shareDividend as % of EPS (Mar Q): 11.25%Record Date: August 21, 2026Auditor Term: 5 yearsMarch 2026 Revenue: ₹110.62 cr
📅 Short termThe stock may experience neutral to slightly positive sentiment leading up to the August 21 record date as investors position for the dividend.
📈 Long termLimited structural impact; the dividend and auditor appointment are routine corporate actions reflecting stable operations.
Key Highlights
Recommended a final dividend of ₹0.70 per equity share of face value ₹10 for FY26.
Fixed August 21, 2026, as the record date for dividend distribution and e-voting eligibility.
Proposed re-appointment of M/S. Nidhi Bansal & Co. as statutory auditors for a 5-year term.
Scheduled the 14th Annual General Meeting for August 28, 2026, via video conferencing.
Reported quarterly revenue of ₹110.62 crore and PAT of ₹9.80 crore for March 2026.
👀 What to Watch
Investors should note the record date of August 21, 2026, to be eligible for the dividend and monitor the AGM outcomes on August 28 for formal shareholder approval.
₹0.70 Final Dividend Recommended by Sat Kartar Life; Record Date Fixed for Aug 21, 2026
Sat Kartar Life Limited has recommended a final dividend of ₹0.70 per equity share for the financial year ended March 31, 2026. This payout is based on a face value of ₹10 per share and follows a strong March 2026 quarter where the company reported a PAT of ₹9.80 crore. The board has fixed August 21, 2026, as the record date to determine shareholder eligibility. Additionally, the company has proposed the re-appointment of its statutory auditors for a further five-year term, subject to shareholder approval at the upcoming AGM on August 28, 2026.
Confidence: HIGH
What changedThe company has declared its final dividend for FY26 and established the timeline for its Annual General Meeting and auditor continuity.
Why it mattersThe dividend signals management's commitment to returning capital to shareholders following a profitable fiscal year. The 5-year auditor re-appointment provides stability in financial oversight.
Final Dividend: ₹0.70 per shareFace Value: ₹10Record Date: August 21, 2026Dividend vs Mar 2026 EPS: 11.25%Auditor Term: 5 years
📅 Short termThe stock may experience neutral to slightly positive sentiment leading up to the ex-dividend date as investors position for the ₹0.70 payout.
📈 Long termLimited; this is a routine corporate action. However, consistent dividend payouts and auditor stability are positive indicators of corporate governance.
Key Highlights
Recommended a final dividend of ₹0.70 per equity share for FY 2025-26
Fixed August 21, 2026, as the record date for dividend distribution and E-voting eligibility
Scheduled the 14th Annual General Meeting (AGM) for August 28, 2026
Proposed re-appointment of M/S. Nidhi Bansal & Co. as statutory auditors for a 5-year term
Dividend payout represents approximately 11.25% of the reported Mar 2026 quarterly EPS of ₹6.22
👀 What to Watch
Investors should note the record date of August 21, 2026; shares must be held in the demat account by this date to receive the dividend. Watch for the AGM results on August 28 for formal approval of the payout and auditor re-appointment.
